Granted Patent
B2
US 12,383,637 · App. 17/570,933 · Granted Aug 12, 2025
Therapeutic agents and uses thereof
Inventors:
Sven-Erik Strand (Lund, SE); Amanda Thuy Tran (Stockholm, SE); Sven-Niklas Anders Axelsson (Bjarred, SE)
Assignee:
Janssen Biotech, Inc.
A61K51/1072A61K47/6803A61K49/16A61K49/221A61K51/1018A61K51/1075A61K51/1093A61K51/1096C07K16/18C07K16/3069C07K16/40G01N33/57434C07K2317/565G01N2333/96455
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
Claims (21)
1. A method for the treatment of castration-resistant prostate cancer (CRPC) in a patient, the method comprising administering a therapeutically effective amount of an agent comprising
(a) an antibody or antigen-binding fragment thereof with specificity for human glandular kallikrein (hK2) and
(b) a cytotoxic moiety comprising 225 Ac,
wherein the antibody or antigen-binding fragment thereof with specificity for hK2 comprises the six complementarity determining regions (CDRs) of antibody 11B6, wherein the heavy chain of the 11B6 antibody comprises SEQ ID NO: 4 and the light chain of the 11B6 antibody comprises SEQ ID NO: 5.
2. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof with specificity for hK2 is selected from the group consisting of 11B6 and antigen-binding fragments thereof, wherein the heavy chain of the 11B6 antibody comprises SEQ ID NO: 4 and the light chain of the 11B6 antibody comprises SEQ ID NO: 5.
3. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises human framework residues.
4. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof with specificity for hK2 comprises at least a portion of an antibody constant region derived from a human antibody.
5. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof with specificity for hK2 is linked indirectly to the cytotoxic moiety.
6. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof with specificity for hK2 is linked directly to the cytotoxic moiety.
7. The method of claim 1 , wherein the agent displays tumor uptake characteristics substantially equivalent to the tumor uptake characteristics of the antibody or antigen-binding fragment thereof with specificity for hK2 alone.
8. The method of claim 1 , wherein the prostate cancer is metastatic CRPC.
9. The method of claim 1 , wherein the patient has prostate cancer and is less than 70 years old at the time of diagnosis of prostate cancer and/or at the time of treatment.
10. The method of claim 1 , wherein the patient is characterized in that a family member has been previously diagnosed with prostate cancer.
11. The method of claim 1 , wherein the patient has previously been treated with one or more prostate cancer therapies.
12. The method of claim 1 , wherein the cytotoxic moiety is linked to the antibody or antigen-binding fragment thereof via a non-phenolic linker.
13. The method of claim 1 , wherein the cytotoxic moiety is linked to the antibody or antigen-binding fragment thereof via a chelating moiety.
14. The method of claim 13 , wherein the chelating moiety comprises a derivatives of 1,4,7,10-tetraazacyclododecane-1,4,7,10, tetraacetic acid (DOTA), a derivative of diethylenetriaminepentaacetic acid (DTPA), a derivative of S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), or a derivatives of 1,4,8,11-tetraazacyclodocedan-1,4,8,11-tetraacetic acid (TETA).
15. The method of claim 13 , wherein the chelating moiety comprises 1,4,7,10-tetraazacyclododecane-1,4,7,10, tetraacetic acid (DOTA).
16. The method of claim 1 , wherein the method reduces the rate of growth of prostatic cancer cells in the patient by at least 10% compared to the observed rate of growth of prostatic cancer cells in the patient prior to the treatment.
17. The method of claim 1 , wherein the method reduces the rate growth of prostatic cancer cells in the patient by at least 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% compared to the observed rate of growth of prostatic cancer cells in the patient prior to the treatment.
18. The method of claim 1 , wherein the agent is administered at a dose of about 1 mg/kg.
Continuity (5)
Continuation
14354617
Provisional Application
61552796
· Oct 28, 2011
References Cited (141)
US 4235871A
· Papahadjopoulos et al.
· 1980
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4822535A
· Ekman et al.
· 1989
[cited by applicant]
US 5851451A
· Takechi et al.
· 1998
[cited by applicant]
US 6326471B1
· Kokolus et al.
· 2001
[cited by applicant]
US 7045605B2
· Bander et al.
· 2006
[cited by applicant]
US 7053042B1
· Denmeade et al.
· 2006
[cited by applicant]
US 7872104B2
· Pettersson et al.
· 2011
[cited by applicant]
US 8481683B2
· King et al.
· 2013
[cited by applicant]
US 8663600B2
· Ulmert
· 2014
[cited by applicant]
US 9345782B2
· Strand et al.
· 2016
[cited by applicant]
US 20020001588A1
· Sinha
· 2002
[cited by applicant]
US 20040219163A1
· Frelinger et al.
· 2004
[cited by applicant]
EP 0213303A2
· 1987
[cited by applicant]
WO 9821365A2
· 1998
[cited by applicant]
WO 0112218A1
· 2001
[cited by applicant]
WO 0227323A1
· 2002
[cited by applicant]
WO 0298897A2
· 2002
[cited by applicant]
WO 2006087374A1
· 2006
[cited by applicant]
WO 2008070569A2
· 2008
[cited by applicant]
WO 2008112003A2
· 2008
[cited by applicant]
WO 2013061083A2
· 2013
[cited by applicant]
U.S. Appl. No. 14/354,617, filed Apr. 28, 2014.
[cited by applicant]
U.S. Appl. No. 15/135,028, filed Apr. 21, 2016.
[cited by applicant]
U.S. Appl. No. 16/679,778, filed Nov. 11, 2019.
[cited by applicant]
Larsson et al., Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide t…
[cited by applicant]
Laune, et al. “Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins” J. Biol. Chem. (1997) 272(49):30937-44.
[cited by applicant]
Lebeau et al., “Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer”, Biological Chemistry, vol. 391, No. 4, Apr. 2010, pp. 333-343.
[cited by applicant]
Leinonen et al., Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries, Clin Chem 2002, 2208-16, 48.
[cited by applicant]
Leinonen et al., Reactivity of anti-PSA monoclonal antibodies with recombinant human kallikrein-2, Tumor Biology, 1999, 35-37, 20.
[cited by applicant]
Lilja, et al., “Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with a1-Antichymotrypsin” Clin. Chem. (1991) 37(9):1618-1625.
[cited by applicant]
Linden et al., Radioimmunotherapy using 1311-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas, Clin Cancer Res 1999, 3287s-3291s, 5(10 Suppl).
[cited by applicant]
Ljungberg et al., 3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations, Cancer Biother Radiopharm 2003, 99-107, 18.
[cited by applicant]
Lovgren, et al., “Production and activation of recombinant hK2 with propeptide mutations resulting in high xpression levels” Eur. J. Biochem. (1999) 266:1050-1055.
[cited by applicant]
Magklara et al., Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue, Urology 2000, 527-532, 56.
[cited by applicant]
Martensson et al., Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy, Clin Can…
[cited by applicant]
Memari et al., Human Tissue Kallikrein 9: Production of Recombinant Proteins and Specific Antibodies, Biol. Chem. 2006, 387:733-740.
[cited by applicant]
Meyers et al., Development of monoclonal antibody imaging of metastatic prostatic carcinoma, Prostate 1989, 209-220, 14.
[cited by applicant]
Meziere, et al., “In Vivo T Helper Cell Response to Retro-Inverso Peptidomimetics” J. Immunol. (1997) 159 (7):3230-3237.
[cited by applicant]
Miederer et al., Adv Drug Deliver Rev 60:1371-82, 2008 (Year: 2008).
[cited by applicant]
Minarik et al., 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy, J. Nucl. Med 2010, 1974-1978, 51.
[cited by applicant]
Monnet, et al. “Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells” J. Biol. Chem. (1999) 274(6):3789-96.
[cited by applicant]
Nilsson et al., Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA, Brit. J Cancer 1997, 789-797, 75(6).
[cited by applicant]
Nurmikko et al., Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA, Clin Chem 2000, 1610-1618, 46.
[cited by applicant]
Orlova et al., Cellular processing of (125)l- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells, Nucl Med Biol., 2000, 827-835, 27.
[cited by applicant]
Oyen et al., Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma, Eur Urol. 2001 294-9, 40(3).
[cited by applicant]
Pajunen, et al., “Cloning, sequencing, expression and characterization of three anti-estradiol-17b Fab fragments” Biochim. Biophys. Acta (1997) 1351:192-202.
[cited by applicant]
Pascalis et al., “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogentic Humanized Monoclonal Antibody”, Th…
[cited by applicant]
Paul, W.E., “Fundamental Immunology”, 3rd Edition, Raven Press, New York (1993) pp. 292-295.
[cited by applicant]
Pessi, et al. “A designed metal-binding protein with a novel fold” Nature (1993) 362(6418):367-9.
[cited by applicant]
Pettersson et al., Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antic…
[cited by applicant]
Piironen et al. Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing, Clin Chem. 2001, 703-711, 47.
[cited by applicant]
Pippin, et al., “Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates” Bioconjug Chem. (1992) 3(4):342-5.
[cited by applicant]
Qiu, et al. “Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting” Nat. Biotechnol. (2007) 25(8):921-9.
[cited by applicant]
Rittenhouse et al., Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate, Clin. Lab Sci. 1998, 275-368, 35.
[cited by applicant]
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity” Proc. Natl. Acad. Sci. (1982) 79 (6):1979-83.
[cited by applicant]
Schettino et al., Impact of fusion of indium-111 capromab pendetide vol. data sets with those from MRI or CT in patients with recurrent prostate cancer, Am J Roentgenol, 2004, 183, 519-524.
[cited by applicant]
Scott, A.M., et al., “Antibody Therapy of Cancer” Nature Rev. Cancer (2012) 12:278-287.
[cited by applicant]
Segars et al., Development of a 4-D digital mouse phantom for molecular imaging research, MOL Imaging Biol 2004, 149-159, 6.
[cited by applicant]
Sgouros et al., Bone marrow dosimetry for radioimmunotherapy: theoretical considerations, J. Nucl. Med., 1993, 689-694, 34.
[cited by applicant]
Siivola et al., Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections, Urology 2000, 682-688, 56.
[cited by applicant]
Sjogreen et al., The LundADose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapy, Cancer Biother. Radiopharm., 2005, 92-97, 20.
[cited by applicant]
Sjogreen-Gleisner et al., Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I ]tositumomab, J. Nucl. Med. Mol. Imaging, 2011, 126-154, 55.
[cited by applicant]
Skerra et al., Alternative non-antibody scaffolds for molecular recognition, Curr Opin Biotechnol. 2007, 295-304, 18(4).
[cited by applicant]
Sklar, et al., “Flow cytometric analysis of ligand-receptor interactions and molecular assemblies” Annu Rev Biophys Biomol Struct. (2002) 31:97-119.
[cited by applicant]
Smith-Jones: Radioimmunotherapy of prostate cancer, Quarterly J. Nucl. Med. & Mol. Imaging Torino, Dec. 2004; vol. 48: 297-304.
[cited by applicant]
Stenman et al., Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen, Tumour Biol. 1999, 1-12, 20.
[cited by applicant]
Strand, et al., “Pharmacokinetic modeling” Med Phys. (1993) 20(2 Pt 2):515-27.
[cited by applicant]
Taneja et al., Imaging in the diagnosis and management of prostate cancer, Rev. Urol. 2004, 101-113, 6.
[cited by applicant]
Thompson, et al., “CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice” Nucleic Acids Research (1994) 22 (…
[cited by applicant]
Thorseti, et al., “Dipeptide Mimics. Conformationally Restricted Inhibitors of Angiotensin-Converting Enzyme”, Biochem Biophys Res Commun., 1993, 111(1):166-71.
[cited by applicant]
Timmermand, et al., “Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6” EJNMMI Research (2014) 4:51, pp. 1-12.
[cited by applicant]
Torizumi et al., Evaluation of Serum Prostate Specific Antigen in Diagnosis of Patients with Prostate Cancer, Radioisotopes 1991, 298-301, 40.
[cited by applicant]
Tramontano, et al., “Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins” J Mol Biol. (1990) 215(1):175-82.
[cited by applicant]
Tremblay et al., Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors, Am J Pathology, 455-459, 150.
[cited by applicant]
UniProtKB Accession No. P07288, Oct. 25, 2017.
[cited by applicant]
UniProtKB Accession No. P20151, Oct. 25, 2017.
[cited by applicant]
Väisänen et al., “Development of sensitive immunoassays for and total human glandular kallikrein 2”, Clinical Chemistry, American Association For Clinical Chemistry, Washington, DC, vol. 50, No. 9, Jan. 1, 2004, pp. 160…
[cited by applicant]
Väisänen et al., Abstract 374: Sensitive Two-site Immunoassays for Measurement of the Free and Total Forms of Human Glandular Kallikrein 2 (hK2), European Urology Supplements, 2002, 1(1):96.
[cited by applicant]
Väisänen et al., Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments, Analytical Chemistry, …
[cited by applicant]
Van Oosten et al., Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool, Translational Oncology, 2011, 71-82, 4.
[cited by applicant]
Vaughan, et al. “Of minibody, camel and bacteriophage” Comb. Chem. High Throughput Screen. (2001) 4(5):417-30.
[cited by applicant]
Veber, et al., “Conformationally restricted bicyclic analogs of somatostatin” Proc. Natl. Acad. Sci. (1978) 75 (6):2636-2640.
[cited by applicant]
Wenske et al., Evaluation of Molecular Forms of Prostate-Specific Antigen and Human Kallikrein 2 in Predicting Biochemical Failure After Radical Prostatectomy, International Journal Of Cancer, Feb. 1, 2009, 124:3, 659-6…
[cited by applicant]
Zhu et al., Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA, Clin Chem. 2003, 97-103.
[cited by applicant]
Akin et al., Imaging of prostate cancer, Radiol Clin North Am. 2007, 207-22, 45(1).
[cited by applicant]
Almagro, et al., “Humanization of antibodies” Frontiers in Bioscience (2008) 13:1619-1633.
[cited by applicant]
Almqvist, et al., “In vitro and in vivo characterization of 177Lu-huA33 A radioimmunoconjugate against colorectal cancer” Nuclear Medicine and Biology (2006) 33:991-998.
[cited by applicant]
Angov “Codon usage: Nature's roadmap to expression and folding of proteins” Biotechnol. J. (2011) 6:650-659.
[cited by applicant]
Anonymous: “Doktorandplats i Medicinsk stralningsfysik”, Internet citation, Oct. 5, 2010, pp. 1-2.
[cited by applicant]
Armstrong et al., Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer, Eur. Urol. 2012, 549-559, 61(3).
[cited by applicant]
Axelsson et al., “Targeting Free Prostate-Specific Antigen for In Vivo Imaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free ProstateSpecific Antigen Alone”, Cancer Bioth…
[cited by applicant]
Bapat et al., Radioiodination of monoclonal antibody for prostate specific antigen, J. of Radioanalytical and Nuclear Chemistry, 2002, 227-230, 253.
[cited by applicant]
Barbas, et al., “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site” Proc. Natl. Acad. Sci. USA (1991) 88:7978-7982.
[cited by applicant]
Bardies, et al., “Quantitative imaging for clinical dosimetry” Nuclear Instruments and Methods in Physics Research A (2006) 569:467-471.
[cited by applicant]
Bast et al., Translational crossroads for biomarkers, Clin Cancer Res. 2005, 6103-8, 11(17).
[cited by applicant]
Becker et al., Sensitive and specific immunodetection of human glandular kallikrein 2 in serum, Clin Chem, 2000, 198-206, 46.
[cited by applicant]
Bianchi, et al. “High level expression and rational From an insoluble to a soluble molecule” J. Mol. Biol. (1994) 236(2):649-59.
[cited by applicant]
Bolch et al., Mird Pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature, J. Nuclear Med. 2009, 477-484, 50.
[cited by applicant]
Borgono et al., Human tissue kallikreins: physiologic roles and applications in cancer, Mol Cancer Res, 2004, 257-280, 2.
[cited by applicant]
Britton et al., Prostate cancer: the contribution of nuclear medicine, BJU Int. 2000, 135-142, 86.
[cited by applicant]
Bunka et al., Aptamers come of age—at last, Nature Reviews: Microbiology 2006, 588-96, 4(8).
[cited by applicant]
Casi, G., et al., “Antibody-drug conjugates: Basic Concepts, Example and Future Perspectives” J. Controlled Rel. (2012) 161:422-428.
[cited by applicant]
Casset et al., A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design, BBRC, 2003, 307, 198-205.
[cited by applicant]
Chengazi et al., Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351), Nucl. Med. 1997, 675-682, 38.
[cited by applicant]
Chothia, et al., “Conformations of immunoglobulin hypervariable regions” Nature (1989) 342(6252):877-883.
[cited by applicant]
Darson et al., Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker, Urology 1997, 857-862, 49.
[cited by applicant]
David et al., “Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen”, Cancer Discovery, American Association For Cancer Research, US, vol. 2, Jan. 1, 2012, pp. 320-327.
[cited by applicant]
Diamandis et al., Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma, Cancer Research, 2002, 295-300, 62.
[cited by applicant]
Drabovich et al., Selection of smart aptamers by methods of kinetic capillary electrophoresis, Anal Chem. 2006, 3171-8, 78(9).
[cited by applicant]
Ensembl, Transcript: KLK2-201 (ENST00000325321), a product of gene ENSG00000167751, Dec. 2017.
[cited by applicant]
Feneley et al., Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer, Prostate Cancer Prostatic Dis. 2000 47-52, 3.
[cited by applicant]
Finlay et al., Development of a dual monoclonal antibody immunoassay for total human kallikrein 2, Clin Chem, 2001, 1218-1224, 47.
[cited by applicant]
Fisher et al., Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors, Prostate 2002, 153-165, 51.
[cited by applicant]
Foote, et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops” J. Mol. Biol. (1992) 224:487-499.
[cited by applicant]
Gao, et al. “Molecular cloning of a proteolytic antibody light chain” J. Biol. Chem. (1994) 269(51):32389-93.
[cited by applicant]
Garkavij et al., 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy, Cancer 2010, 1084-1092, 116.
[cited by applicant]
GenBank Accession No. AAF08275.1, Nov. 15, 1999.
[cited by applicant]
GenBank Accession No. AAF08277.1, Nov. 15, 1999.
[cited by applicant]
Goldenberg, D.M., “Radiolabelled monoclonal antibodies in the treatment of metastatic cancer” Current Onocology (2007) 14(1):39-42.
[cited by applicant]
Hekim et al., “Novel Peptide Inhibitors of Human Kallikrein 2”, Journal Of Biological Chemistry, vol. 281, No. 18, Jan. 1, 2006, pp. 12555-12560.
[cited by applicant]
Holliger, P., et al., “Engineered Antibody Fragments and the Rise of Single Domains” Nature Biotech. (2005) 23:1126-1136.
[cited by applicant]
Hoppe-Seyler et al., Peptide aptamers: powerful new tools for molecular medicine, J. Mol. Med., 2000, 426-30.
[cited by applicant]
Hricak et al., Advances in imaging in the postoperative patient with a rising prostate-specific antigen level, Seminars in Oncology 2003, 616-634, 30.
[cited by applicant]
Hsieh et al., Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D, Cancer Res. 1997, 2651-6, 57.
[cited by applicant]
Huang, et al., “A Time-Efficient, Linear-Space Local Similarity Algorithm” Adv. Appl. Math. (1991) 12:337-357.
[cited by applicant]
Hudson, P.J., et al., “Engineered Antibodies” Nature Med. (2003) 9:129-134.
[cited by applicant]
Kairemo et al., Radioimmunotherapy with 90Y-labeled monoclonal antibodies in a nude mouse ovarian cancer model, Acta Oncology, 1993, 801-805, 32.
[cited by applicant]
Keenan, et al., “RADAR Realistic Animal Model Series for Dose Assessment” J Nucl Med (2010) 51:471-476.
[cited by applicant]
Kellof et al., Challenges in clinical prostate cancer: role of imaging, AJR 2009, 1455-1470, 192.
[cited by applicant]
Kim et al., The unfolding treatment landscape for men with castration-resistant prostate cancer, Clin. Investig., 2011, 1533-44, 1(11).
[cited by applicant]
Krebber, et al., “Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system” Journal of Immunological Methods (1997) 201:35-55.
[cited by applicant]
Ladner, R.C. “Antibodies cut down to size” Nat. Biotechnol. (2007) 25(8):875-7.
[cited by applicant]
Larrson et al., Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for pre-clinical dosimetry studies, Acta Oncol. 2011, 973-80, 50(6).
[cited by applicant]
Larsson et al., Mouse S-Factors Based on Monte Carlo Simulations in the Anatomical Realistic Moby Phantom for Internal Dosimetry, Cancer Biother Radiopharm 2007, 438-442, 22.
[cited by applicant]